NON-AMINE BASED ANALOGS OF LAVENDUSTIN-A AS PROTEIN-TYROSINE KINASE INHIBITORS

被引:41
作者
SMYTH, MS
STEFANOVA, I
HARTMANN, F
HORAK, ID
OSHEROV, N
LEVITZKI, A
BURKE, TR
机构
[1] NIH, DIV CANC TREATMENT,DEV THERAPEUT PROGRAM, MED CHEM LAB,BLDG 37,ROOM 5C06, BETHESDA, MD 20892 USA
[2] NCI, DIV CANC BIOL DIAG & CTR, METAB BRANCH, BETHESDA, MD 20892 USA
[3] HEBREW UNIV JERUSALEM, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL
关键词
D O I
10.1021/jm00072a022
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The fermentation product lavendustin A (1) is a protein-tyrosine kinase (PTK) inhibitor whose active pharmacophore has previously been shown to reside in the more simplified salicyl-containing benzylamine 2. Amine 2 bears some structural resemblance to two other natural product PTK inhibitors, erbstatin (3) and piceatannol (4). Non-amine containing analogues of 2 were therefore synthesized which incorporated additional aspects of either erbstatin or piceatannol. Examination of these inhibitors in immunoprecipitated p56lck, epidermal growth factor receptor (EGFR), and c-erb B-2/HER 2/neu PTK preparations showed that compound 12 (IC50 = 60 nM) was one of the most potent p56lck inhibitors reported to date. These results demonstrate that nitrogen is not an essential component of the lavendustin A pharmacophore 2 and that 1,2-diarylethanes and -ethenes bearing a salicyl moiety appear to be valuable structural motifs for the construction of extremely potent PTK inhibitors.
引用
收藏
页码:3010 / 3014
页数:5
相关论文
共 26 条
  • [1] BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409
  • [2] BURKE T R JR, 1992, Drugs of the Future, V17, P119
  • [3] BICYCLIC COMPOUNDS AS RING-CONSTRAINED INHIBITORS OF PROTEIN-TYROSINE KINASE-P56LCK
    BURKE, TR
    LIM, B
    MARQUEZ, VE
    LI, ZH
    BOLEN, JB
    STEFANOVA, I
    HORAK, ID
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (04) : 425 - 432
  • [4] PHOSPHONATE-CONTAINING INHIBITORS OF TYROSINE-SPECIFIC PROTEIN-KINASES
    BURKE, TR
    LI, ZH
    BOLEN, JB
    MARQUEZ, VE
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (05) : 1577 - 1581
  • [5] STRUCTURAL INFLUENCES OF STYRYL-BASED INHIBITORS ON EPIDERMAL GROWTH-FACTOR RECEPTOR AND P56LCK TYROSINE-SPECIFIC PROTEIN-KINASES
    BURKE, TR
    LI, ZH
    BOLEN, JB
    MARQUEZ, VE
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1991, 1 (03) : 165 - 168
  • [6] ARYLAMIDES OF HYDROXYLATED ISOQUINOLINES AS PROTEIN-TYROSINE KINASE INHIBITORS
    BURKE, TR
    FORD, H
    OSHEROV, N
    LEVITZKI, A
    STEFANOVA, I
    HORAK, ID
    MARQUEZ, VE
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1992, 2 (12) : 1771 - 1774
  • [7] PROTEIN-TYROSINE KINASE INHIBITION - MECHANISM-BASED DISCOVERY OF ANTITUMOR AGENTS
    CHANG, CJ
    GEAHLEN, RL
    [J]. JOURNAL OF NATURAL PRODUCTS, 1992, 55 (11): : 1529 - 1560
  • [8] SYNTHESIS AND EVALUATION OF NEW PROTEIN-TYROSINE KINASE INHIBITORS .1. PYRIDINE-CONTAINING STILBENES AND AMIDES
    CUSHMAN, M
    NAGARATHNAM, D
    GOPAL, D
    GEAHLEN, RL
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1991, 1 (04) : 211 - 214
  • [9] SYNTHESIS AND EVALUATION OF NEW PROTEIN-TYROSINE KINASE INHIBITORS .2. PHENYLHYDRAZONES
    CUSHMAN, M
    NAGARATHNAM, D
    GOPAL, D
    GEAHLEN, RL
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1991, 1 (04) : 215 - 218
  • [10] Dobrusin EM, 1992, ANNU REP MED CHEM, V27, P169